less than 1 minute read

Our lab has been selected by the Paul G. Allen Family Foundation’s Allen Distinguished Investigator (ADI) Program to investigate the fundamental cellular biology of Alzheimer’s Disease in completely new ways.

Working with the Kampmann and Kokel labs, we will be combining our systems pharmacology, functional genomics, and zebrafish behavioral screening platforms with data on half a million compounds from the Prusiner lab to find new combinations of targets controlling Alzheimer’s Disease processes in human cells. We’ll explore the consequences of new target combinations and compounds that modulate them on the protein homeostasis network with the Gestwicki lab.

PGAF ADI Image

Tags:

Categories:

Updated: